As reported in In-Pharma Technologist, Genzyme will sell its pharmaceuticals Intermediates business to International Chemical Investors Group (ICIG). Thus, Genzyme has fulfilled its goal of selling its 3 non-pharma businesses (genetic testing, diagnostics and pharma intermediates) to allow it to focus on the core pharma business.
The pharma intermediates unit makes lipids, peptides, carbohydrates, oligos and custom small molecules for pharma customers. It will be renamed Corden Pharma and will continue to operate out of Liestal, Switzerland. ICIG will continue to make clinical trial supplies for Genzyme's phase III Gaucher's disease drug, eliglustat tartrate. ICIG will make make other drugs too used in early clinical trials.
Posted by Bruce Lehr Feb 2nd 2011.